{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:17:17Z","timestamp":1793643437653,"version":"4.5.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11910-018-0901-z","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T07:47:20Z","timestamp":1539762440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update"],"prefix":"10.1007","volume":"18","author":[{"given":"Rocio","family":"Garcia-Santibanez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"901_CR1","first-page":"1051","volume-title":"Peripheral Neuropathy","author":"A Harding","year":"1993","unstructured":"Harding A. Inherited neuronal atrophy and degeneration predominantly of lower motor neurons. In: Dyck PJ, Thomas PK, editors. Peripheral Neuropathy. 3rd ed. Philadelphia: Saunders; 1993. p. 1051\u201363.","edition":"3"},{"issue":"11","key":"901_CR2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrneurol.2014.184","volume":"10","author":"B Swinnen","year":"2014","unstructured":"Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661\u201370.","journal-title":"Nat Rev Neurol"},{"issue":"13","key":"901_CR3","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1212\/WNL.0000000000003772","volume":"88","author":"B Bansagi","year":"2017","unstructured":"Bansagi B, Griffin H, Whittaker RG, Antoniadi T, Evangelista T, Miller J, et al. Genetic heterogeneity of motor neuropathies. Neurology. 2017;88(13):1226\u201334.","journal-title":"Neurology"},{"issue":"2","key":"901_CR4","doi-asserted-by":"crossref","first-page":"R195","DOI":"10.1093\/hmg\/ddh226","volume":"13","author":"J Irobi","year":"2004","unstructured":"Irobi J, De Jonghe P, Timmerman V. Molecular genetics of distal hereditary motor neuropathies. Hum Mol Genet. 2004;13(2):R195\u2013202.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"901_CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1212\/WNL.0000000000003504","volume":"88","author":"S Lefter","year":"2017","unstructured":"Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017;88(3):304\u201313.","journal-title":"Neurology"},{"issue":"5","key":"901_CR6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/humu.23189","volume":"38","author":"A Echaniz-Laguna","year":"2017","unstructured":"Echaniz-Laguna A, Geuens T, Petiot P, Pereon Y, Adriaenssens E, Haidar M, et al. Axonal neuropathies due to mutations in small heat shock proteins: clinical, genetic, and functional insights into novel mutations. Hum Mutat. 2017;38(5):556\u201368.","journal-title":"Hum Mutat"},{"key":"901_CR7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fmolb.2016.00081","volume":"3","author":"V Lupo","year":"2016","unstructured":"Lupo V, Aguado C, Knecht E, Espinos C. Chaperonopathies: spotlight on hereditary motor neuropathies. Front Mol Biosci. 2016;3:81.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"901_CR8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/jns.12252","volume":"23","author":"H Tanabe","year":"2018","unstructured":"Tanabe H, Higuchi Y, Yuan JH, Hashiguchi A, Yoshimura A, Ishihara S, et al. Clinical and genetic features of Charcot-Marie-tooth disease 2F and hereditary motor neuropathy 2B in Japan. J Peripher Nerv Syst. 2018;23(1):40\u20138.","journal-title":"J Peripher Nerv Syst"},{"issue":"10","key":"901_CR9","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/brain\/awx187","volume":"140","author":"E Adriaenssens","year":"2017","unstructured":"Adriaenssens E, Geuens T, Baets J, Echaniz-Laguna A, Timmerman V. Novel insights in the disease biology of mutant small heat shock proteins in neuromuscular diseases. Brain. 2017;140(10):2541\u20139.","journal-title":"Brain"},{"issue":"1","key":"901_CR10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ene.13478","volume":"25","author":"A Cortese","year":"2018","unstructured":"\u2022 Cortese A, Laura M, Casali C, Nishino I, Hayashi YK, Magri S, et al. Altered TDP-43-dependent splicing in HSPB8-related distal hereditary motor neuropathy and myofibrillar myopathy. Eur J Neurol. 2018;25(1):154\u201363 The authors highlight the potential role of TDP-43 in the pathogenesis of HSPB8 mutations.","journal-title":"Eur J Neurol"},{"issue":"21","key":"901_CR11","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1073\/pnas.1422001112","volume":"112","author":"SY Tsai","year":"2015","unstructured":"Tsai SY, Pokrass MJ, Klauer NR, Nohara H, Su TP. Sigma-1 receptor regulates tau phosphorylation and axon extension by shaping p35 turnover via myristic acid. Proc Natl Acad Sci U S A. 2015;112(21):6742\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"901_CR12","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/hmg\/ddw220","volume":"25","author":"E Gregianin","year":"2016","unstructured":"Gregianin E, Pallafacchina G, Zanin S, Crippa V, Rusmini P, Poletti A, et al. Loss-of-function mutations in the SIGMAR1 gene cause distal hereditary motor neuropathy by impairing ER-mitochondria tethering and Ca2+ signalling. Hum Mol Genet. 2016;25(17):3741\u201353.","journal-title":"Hum Mol Genet"},{"key":"901_CR13","doi-asserted-by":"crossref","first-page":"2329048X1666991","DOI":"10.1177\/2329048X16669912","volume":"3","author":"JJY Lee","year":"2016","unstructured":"Lee JJY, van Karnebeek CDM, Drogemoller B, Shyr C, Tarailo-Graovac M, Eydoux P, et al. Further validation of the SIGMAR1 c.151+1G>T mutation as cause of distal hereditary motor neuropathy. Child Neurol Open. 2016;3:2329048X16669912.","journal-title":"Child Neurol Open"},{"issue":"24","key":"901_CR14","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1212\/WNL.0000000000001680","volume":"84","author":"X Li","year":"2015","unstructured":"Li X, Hu Z, Liu L, Xie Y, Zhan Y, Zi X, et al. A SIGMAR1 splice-site mutation causes distal hereditary motor neuropathy. Neurology. 2015;84(24):2430\u20137.","journal-title":"Neurology"},{"issue":"2","key":"901_CR15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/ene.13519","volume":"25","author":"R Nandhagopal","year":"2018","unstructured":"Nandhagopal R, Meftah D, Al-Kalbani S, Scott P. Recessive distal motor neuropathy with pyramidal signs in an Omani kindred: underlying novel mutation in the SIGMAR1 gene. Eur J Neurol. 2018;25(2):395\u2013403.","journal-title":"Eur J Neurol"},{"issue":"6","key":"901_CR16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ajhg.2012.09.019","volume":"91","author":"KE Barwick","year":"2012","unstructured":"Barwick KE, Wright J, Al-Turki S, McEntagart MM, Nair A, Chioza B, et al. Defective presynaptic choline transport underlies hereditary motor neuropathy. Am J Hum Genet. 2012;91(6):1103\u20137.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"901_CR17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/cge.13369","volume":"94","author":"K Hamanaka","year":"2018","unstructured":"Hamanaka K, Takahashi K, Miyatake S, Mitsuhashi S, Hamanoue H, Miyaji Y, et al. Confirmation of SLC5A7-related distal hereditary motor neuropathy 7 in a family outside Wales. Clin Genet. 2018;94(2):274\u20135.","journal-title":"Clin Genet"},{"issue":"3","key":"901_CR18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/practneurol-2015-001307","volume":"16","author":"G Ingram","year":"2016","unstructured":"Ingram G, Barwick KE, Hartley L, McEntagart M, Crosby AH, Llewelyn G, et al. Distal hereditary motor neuropathy with vocal cord paresis: from difficulty in choral singing to a molecular genetic diagnosis. Pract Neurol. 2016;16(3):247\u201351.","journal-title":"Pract Neurol"},{"issue":"2","key":"901_CR19","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1212\/NXG.0000000000000222","volume":"4","author":"CG Salter","year":"2018","unstructured":"Salter CG, Beijer D, Hardy H, Barwick KES, Bower M, Mademan I, et al. Truncating SLC5A7 mutations underlie a spectrum of dominant hereditary motor neuropathies. Neurol Genet. 2018;4(2):e222.","journal-title":"Neurol Genet"},{"issue":"5","key":"901_CR20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/375039","volume":"72","author":"A Antonellis","year":"2003","unstructured":"Antonellis A, Ellsworth RE, Sambuughin N, Puls I, Abel A, Lee-Lin SQ, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet. 2003;72(5):1293\u20139.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"901_CR21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/awx058","volume":"140","author":"PC Tsai","year":"2017","unstructured":"\u2022 Tsai PC, Soong BW, Mademan I, Huang YH, Liu CR, Hsiao CT, et al. A recurrent WARS mutation is a novel cause of autosomal dominant distal hereditary motor neuropathy. Brain. 2017;140(5):1252\u201366 This is the first study to identify WARS mutations as a cause of autosomal dominant distal hereditary motor neuropathy and provides a thorough characterization of the cellular and biochemical sequelae of these mutations using an in vitro model.","journal-title":"Brain"},{"issue":"Pt 10","key":"901_CR22","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awh590","volume":"128","author":"K Sivakumar","year":"2005","unstructured":"Sivakumar K, Kyriakides T, Puls I, Nicholson GA, Funalot B, Antonellis A, et al. Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain. 2005;128(Pt 10):2304\u201314.","journal-title":"Brain"},{"issue":"4","key":"901_CR23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10048-017-0524-6","volume":"18","author":"P Sancho","year":"2017","unstructured":"Sancho P, Sanchez-Monteagudo A, Collado A, Marco-Marin C, Dominguez-Gonzalez C, Camacho A, et al. A newly distal hereditary motor neuropathy caused by a rare AIFM1 mutation. Neurogenetics. 2017;18(4):245\u201350.","journal-title":"Neurogenetics"},{"issue":"5","key":"901_CR24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ajhg.2013.10.006","volume":"93","author":"CJ Sumner","year":"2013","unstructured":"Sumner CJ, d\u2019Ydewalle C, Wooley J, Fawcett KA, Hernandez D, Gardiner AR, et al. A dominant mutation in FBXO38 causes distal spinal muscular atrophy with calf predominance. Am J Hum Genet. 2013;93(5):976\u201383.","journal-title":"Am J Hum Genet"},{"issue":"19","key":"901_CR25","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1212\/WNL.0b013e3182735d36","volume":"79","author":"A Chio","year":"2012","unstructured":"Chio A, Calvo A, Mazzini L, Cantello R, Mora G, Moglia C, et al. Extensive genetics of ALS: a population-based study in Italy. Neurology. 2012;79(19):1983\u20139.","journal-title":"Neurology"},{"issue":"5","key":"901_CR26","doi-asserted-by":"crossref","first-page":"1017 e17","DOI":"10.1016\/j.neurobiolaging.2011.12.003","volume":"33","author":"MJ Kwon","year":"2012","unstructured":"Kwon MJ, Baek W, Ki CS, Kim HY, Koh SH, Kim JW, et al. Screening of the SOD1, FUS, TARDBP, ANG, and OPTN mutations in Korean patients with familial and sporadic ALS. Neurobiol Aging. 2012;33(5):1017 e17\u201323.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"901_CR27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.0b013e31825dceca","volume":"79","author":"S Lattante","year":"2012","unstructured":"Lattante S, Conte A, Zollino M, Luigetti M, Del Grande A, Marangi G, et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology. 2012;79(1):66\u201372.","journal-title":"Neurology"},{"issue":"17","key":"901_CR28","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1093\/hmg\/dds199","volume":"21","author":"M Blitterswijk van","year":"2012","unstructured":"van Blitterswijk M, van Es MA, Hennekam EA, Dooijes D, van Rheenen W, Medic J, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21(17):3776\u201384.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"901_CR29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ana.24306","volume":"77","author":"J Cady","year":"2015","unstructured":"Cady J, Allred P, Bali T, Pestronk A, Goate A, Miller TM, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015;77(1):100\u201313.","journal-title":"Ann Neurol"},{"issue":"3","key":"901_CR30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1212\/WNL.0000000000004109","volume":"89","author":"SB Gibson","year":"2017","unstructured":"\u2022 Gibson SB, Downie JM, Tsetsou S, Feusier JE, Figueroa KP, Bromberg MB, et al. The evolving genetic risk for sporadic ALS. Neurology. 2017;89(3):226\u201333 By incoporating variant pathogenicity (based on prediction software) and variant frequency data, this study showed that ~17% of sporadic ALS had a rare and deleterious or pathogenic variant in an ALS-associate gene, a value lower than other recent estimates but still of substantial clinical significance.","journal-title":"Neurology"},{"key":"901_CR31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fnmol.2017.00370","volume":"10","author":"J Cooper-Knock","year":"2017","unstructured":"Cooper-Knock J, Robins H, Niedermoser I, Wyles M, Heath PR, Higginbottom A, et al. Targeted genetic screen in amyotrophic lateral sclerosis reveals novel genetic variants with synergistic effect on clinical phenotype. Front Mol Neurosci. 2017;10:370.","journal-title":"Front Mol Neurosci"},{"issue":"7","key":"901_CR32","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1007\/s00415-017-8540-x","volume":"264","author":"MP Giannoccaro","year":"2017","unstructured":"Giannoccaro MP, Bartoletti-Stella A, Piras S, Pession A, De Massis P, Oppi F, et al. Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature. J Neurol. 2017;264(7):1426\u201333.","journal-title":"J Neurol"},{"issue":"7650","key":"901_CR33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","volume":"544","author":"LA Becker","year":"2017","unstructured":"\u2022 Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367\u201371 This study identified ataxin-2 as a potential disease modifier, a finding warranting further investigation in ALS patients, and provides rationale to consider ataxin-2 as a therapeutic target in future clinical trials.","journal-title":"Nature"},{"issue":"2","key":"901_CR34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245\u201356.","journal-title":"Neuron"},{"issue":"2","key":"901_CR35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257\u201368.","journal-title":"Neuron"},{"issue":"3","key":"901_CR36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00401-018-1823-1","volume":"135","author":"T Arzberger","year":"2018","unstructured":"Arzberger T, Schludi MH, Lehmer C, Schmid B, Edbauer D. RNA versus protein toxicity in C9orf72 ALS\/FTLD. Acta Neuropathol. 2018;135(3):475\u20139.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"901_CR37","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41582-018-0047-2","volume":"14","author":"R Balendra","year":"2018","unstructured":"Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14(9):544\u201358.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"901_CR38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.neuron.2014.12.010","volume":"84","author":"X Wen","year":"2014","unstructured":"Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS\/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84(6):1213\u201325.","journal-title":"Neuron"},{"issue":"3","key":"901_CR39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.4490","volume":"24","author":"Y Shi","year":"2018","unstructured":"Shi Y, Lin S, Staats KA, Li Y, Chang WH, Hung ST, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS\/FTD human induced motor neurons. Nat Med. 2018;24(3):313\u201325.","journal-title":"Nat Med"},{"issue":"208","key":"901_CR40","doi-asserted-by":"crossref","first-page":"208ra149","DOI":"10.1126\/scitranslmed.3007529","volume":"5","author":"D Sareen","year":"2013","unstructured":"Sareen D, O\u2019Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5(208):208ra149.","journal-title":"Sci Transl Med"},{"issue":"8","key":"901_CR41","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nn.4065","volume":"18","author":"M Prudencio","year":"2015","unstructured":"Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci. 2015;18(8):1175\u201382.","journal-title":"Nat Neurosci"},{"issue":"1","key":"901_CR42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00401-015-1429-9","volume":"130","author":"J Cooper-Knock","year":"2015","unstructured":"Cooper-Knock J, Higginbottom A, Stopford MJ, Highley JR, Ince PG, Wharton SB, et al. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathol. 2015;130(1):63\u201375.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"901_CR43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00401-017-1725-7","volume":"134","author":"M DeJesus-Hernandez","year":"2017","unstructured":"DeJesus-Hernandez M, Finch NA, Wang X, Gendron TF, Bieniek KF, Heckman MG, et al. In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol. 2017;134(2):255\u201369.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"901_CR44","doi-asserted-by":"crossref","first-page":"E1111","DOI":"10.1073\/pnas.1620293114","volume":"114","author":"KY Shi","year":"2017","unstructured":"\u2022 Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S, et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc Natl Acad Sci U S A. 2017;114(7):E1111\u2013E7 This study provided important insights into the the role of dysfunctional nuclear transport in C9 associated ALS pathophysiology.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"901_CR45","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cell.2017.12.030","volume":"172","author":"Q Guo","year":"2018","unstructured":"Guo Q, Lehmer C, Martinez-Sanchez A, Rudack T, Beck F, Hartmann H, et al. In situ structure of neuronal C9orf72 poly-GA aggregates reveals proteasome recruitment. Cell. 2018;172(4):696\u2013705 e12.","journal-title":"Cell"},{"issue":"6","key":"901_CR46","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00401-015-1476-2","volume":"130","author":"IR Mackenzie","year":"2015","unstructured":"Mackenzie IR, Frick P, Grasser FA, Gendron TF, Petrucelli L, Cashman NR, et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 2015;130(6):845\u201361.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"901_CR47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00401-015-1450-z","volume":"130","author":"MH Schludi","year":"2015","unstructured":"Schludi MH, May S, Grasser FA, Rentzsch K, Kremmer E, Kupper C, et al. Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol. 2015;130(4):537\u201355.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"901_CR48","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.neuron.2014.07.041","volume":"83","author":"Z Su","year":"2014","unstructured":"Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD\/ALS. Neuron. 2014;83(5):1043\u201350.","journal-title":"Neuron"},{"key":"901_CR49","doi-asserted-by":"crossref","first-page":"23204","DOI":"10.1038\/srep23204","volume":"6","author":"A Atanasio","year":"2016","unstructured":"Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;6:23204.","journal-title":"Sci Rep"},{"issue":"347","key":"901_CR50","doi-asserted-by":"crossref","first-page":"347ra93","DOI":"10.1126\/scitranslmed.aaf6038","volume":"8","author":"A Burberry","year":"2016","unstructured":"Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8(347):347ra93.","journal-title":"Sci Transl Med"},{"issue":"6279","key":"901_CR51","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.aaf1064","volume":"351","author":"JG O\u2019Rourke","year":"2016","unstructured":"O\u2019Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, Muhammad AK, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351(6279):1324\u20139.","journal-title":"Science"},{"issue":"1","key":"901_CR52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40478-016-0324-5","volume":"4","author":"PM Sullivan","year":"2016","unstructured":"Sullivan PM, Zhou X, Robins AM, Paushter DH, Kim D, Smolka MB, et al. The ALS\/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol Commun. 2016;4(1):51.","journal-title":"Acta Neuropathol Commun"},{"issue":"11","key":"901_CR53","doi-asserted-by":"crossref","first-page":"e1006443","DOI":"10.1371\/journal.pgen.1006443","volume":"12","author":"J Ugolino","year":"2016","unstructured":"Ugolino J, Ji YJ, Conchina K, Chu J, Nirujogi RS, Pandey A, et al. Loss of C9orf72 enhances Autophagic activity via deregulated mTOR and TFEB signaling. PLoS Genet. 2016;12(11):e1006443.","journal-title":"PLoS Genet"},{"issue":"15","key":"901_CR54","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.15252\/embj.201694401","volume":"35","author":"CP Webster","year":"2016","unstructured":"Webster CP, Smith EF, Bauer CS, Moller A, Hautbergue GM, Ferraiuolo L, et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 2016;35(15):1656\u201376.","journal-title":"EMBO J"},{"issue":"9","key":"901_CR55","doi-asserted-by":"crossref","first-page":"e1601167","DOI":"10.1126\/sciadv.1601167","volume":"2","author":"M Yang","year":"2016","unstructured":"Yang M, Liang C, Swaminathan K, Herrlinger S, Lai F, Shiekhattar R, et al. A C9ORF72\/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Sci Adv. 2016;2(9):e1601167.","journal-title":"Sci Adv"},{"issue":"20","key":"901_CR56","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.15252\/embj.201797568","volume":"36","author":"FB Gao","year":"2017","unstructured":"Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J. 2017;36(20):2931\u201350.","journal-title":"EMBO J"},{"key":"901_CR57","unstructured":"Fomin V, Richard P, Hoque M, Li C, Gu Z, Fissore-O\u2019Leary M, et al. The C9ORF72 gene, implicated in ALS\/FTD, encodes a protein that functions in control of endothelin and glutamate signaling. Mol Cell Biol. 2018."},{"issue":"3","key":"901_CR58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"G Biomarkers Definitions Working","year":"2001","unstructured":"Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","volume":"9","author":"D Petrov","year":"2017","unstructured":"Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"901_CR60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mus.24979","volume":"53","author":"M Benatar","year":"2016","unstructured":"\u2022 Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, et al. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve. 2016;53(2):169\u201382 This is a very well written, thorough, comprehensive review of ALS biomarkers and provides a nice commentary on the importance of identifying reliable ALS biomarkers for use in clinical practice and investigational studies.","journal-title":"Muscle Nerve"},{"issue":"1","key":"901_CR61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13311-016-0503-x","volume":"14","author":"LT Vu","year":"2017","unstructured":"Vu LT, Bowser R. Fluid-based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14(1):119\u201334.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"901_CR62","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1212\/WNL.0000000000004761","volume":"90","author":"E Feneberg","year":"2018","unstructured":"\u2022 Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90(1):e22\u201330 This multicenter study highlights the utility of neurofilaments as a reliable diagnostic biomarker in ALS.","journal-title":"Neurology"},{"issue":"10","key":"901_CR63","doi-asserted-by":"crossref","first-page":"e0164625","DOI":"10.1371\/journal.pone.0164625","volume":"11","author":"Z Xu","year":"2016","unstructured":"Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One. 2016;11(10):e0164625.","journal-title":"PLoS One"},{"issue":"1","key":"901_CR64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.25276","volume":"84","author":"M Benatar","year":"2018","unstructured":"Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130\u20139.","journal-title":"Ann Neurol"},{"issue":"12","key":"901_CR65","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","volume":"88","author":"SR Shepheard","year":"2017","unstructured":"\u2022 Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137\u201343 This multicenter study highlights the utility of p75NTR ECD as a reliable, easily accessible, biomarker of disease progression in ALS.","journal-title":"Neurology"},{"issue":"1","key":"901_CR66","doi-asserted-by":"crossref","first-page":"e87398","DOI":"10.1371\/journal.pone.0087398","volume":"9","author":"SR Shepheard","year":"2014","unstructured":"Shepheard SR, Chataway T, Schultz DW, Rush RA, Rogers ML. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS One. 2014;9(1):e87398.","journal-title":"PLoS One"},{"issue":"12","key":"901_CR67","first-page":"1505","volume":"70","author":"XW Su","year":"2013","unstructured":"Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol. 2013;70(12):1505\u201311.","journal-title":"JAMA Neurol"},{"issue":"2","key":"901_CR68","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.25143","volume":"83","author":"AG Thompson","year":"2018","unstructured":"Thompson AG, Gray E, Thezenas ML, Charles PD, Evetts S, Hu MT, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. 2018;83(2):258\u201368.","journal-title":"Ann Neurol"},{"issue":"22","key":"901_CR69","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1523\/JNEUROSCI.3582-16.2017","volume":"37","author":"ML Hoye","year":"2017","unstructured":"Hoye ML, Koval ED, Wegener AJ, Hyman TS, Yang C, O\u2019Brien DR, et al. MicroRNA profiling reveals marker of motor neuron disease in ALS models. J Neurosci. 2017;37(22):5574\u201386.","journal-title":"J Neurosci"},{"issue":"9","key":"901_CR70","first-page":"2561","volume":"141","author":"ML Hoye","year":"2018","unstructured":"\u2022 Hoye ML, Regan MR, Jensen LA, Lake AM, Reddy LV, Vidensky S, et al. Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis. Brain. 2018;141(9):2561\u201375 This study highlights a novel mechanism by which the motor neuron derived microRNA-218 may contribute to ALS pathogenesis and raises the possibility of microRNA-218 as a potential therapeutic target in ALS.","journal-title":"Brain"},{"issue":"3","key":"901_CR71","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s12035-017-0537-z","volume":"55","author":"P Rinchetti","year":"2018","unstructured":"Rinchetti P, Rizzuti M, Faravelli I, Corti S. MicroRNA metabolism and dysregulation in amyotrophic lateral sclerosis. Mol Neurobiol. 2018;55(3):2617\u201330.","journal-title":"Mol Neurobiol"},{"issue":"11","key":"901_CR72","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/jnnp-2015-310509","volume":"86","author":"C Neuwirth","year":"2015","unstructured":"Neuwirth C, Barkhaus PE, Burkhardt C, Castro J, Czell D, de Carvalho M, et al. Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the motor unit number index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry. 2015;86(11):1172\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"901_CR73","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.clinph.2018.04.614","volume":"129","author":"C Neuwirth","year":"2018","unstructured":"Neuwirth C, Braun N, Claeys KG, Bucelli R, Fournier C, Bromberg M, et al. Implementing motor unit number index (MUNIX) in a large clinical trial: real world experience from 27 centres. Clin Neurophysiol. 2018;129(8):1756\u201362.","journal-title":"Clin Neurophysiol"},{"issue":"3","key":"901_CR74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/mus.24128","volume":"49","author":"SB Rutkove","year":"2014","unstructured":"Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, et al. Electrical impedance myography correlates with standard measures of ALS severity. Muscle Nerve. 2014;49(3):441\u20133.","journal-title":"Muscle Nerve"},{"issue":"11","key":"901_CR75","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11910-017-0793-3","volume":"17","author":"B Sanchez","year":"2017","unstructured":"Sanchez B, Rutkove SB. Present uses, future applications, and technical underpinnings of electrical impedance Myography. Curr Neurol Neurosci Rep. 2017;17(11):86.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Pt 9","key":"901_CR76","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/brain\/awl172","volume":"129","author":"S Vucic","year":"2006","unstructured":"Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain. 2006;129(Pt 9):2436\u201346.","journal-title":"Brain"},{"issue":"9","key":"901_CR77","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.clinph.2010.12.062","volume":"122","author":"S Vucic","year":"2011","unstructured":"Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol. 2011;122(9):1860\u20136.","journal-title":"Clin Neurophysiol"},{"issue":"Pt 6","key":"901_CR78","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/brain\/awn071","volume":"131","author":"S Vucic","year":"2008","unstructured":"Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131(Pt 6):1540\u201350.","journal-title":"Brain"},{"issue":"11","key":"901_CR79","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jamaneurol.2015.1872","volume":"72","author":"N Geevasinga","year":"2015","unstructured":"Geevasinga N, Menon P, Nicholson GA, Ng K, Howells J, Kril JJ, et al. Cortical function in asymptomatic carriers and patients with C9orf72 amyotrophic lateral sclerosis. JAMA Neurol. 2015;72(11):1268\u201374.","journal-title":"JAMA Neurol"},{"issue":"24","key":"901_CR80","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1212\/WNL.0000000000003427","volume":"87","author":"MJ Alshikho","year":"2016","unstructured":"Alshikho MJ, Zurcher NR, Loggia ML, Cernasov P, Chonde DB, Izquierdo Garcia D, et al. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016;87(24):2554\u201361.","journal-title":"Neurology"},{"issue":"Pt 6","key":"901_CR81","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/brain\/awu090","volume":"137","author":"J Kassubek","year":"2014","unstructured":"Kassubek J, Muller HP, Del Tredici K, Brettschneider J, Pinkhardt EH, Lule D, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain. 2014;137(Pt 6):1733\u201340.","journal-title":"Brain"},{"issue":"1","key":"901_CR82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13311-016-0484-9","volume":"14","author":"RA Menke","year":"2017","unstructured":"Menke RA, Agosta F, Grosskreutz J, Filippi M, Turner MR. Neuroimaging endpoints in amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14(1):11\u201323.","journal-title":"Neurotherapeutics"},{"key":"901_CR83","unstructured":"FDA Approves Drug to Treat ALS [press release]. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm557102.htm , May 5, 2017; 2017."},{"issue":"sup1","key":"901_CR84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/21678421.2017.1363780","volume":"18","author":"Edaravone Als 16 Study G","year":"2017","unstructured":"Edaravone Als 16 Study G. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):11\u20139.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7\u20138","key":"901_CR85","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/21678421.2014.959024","volume":"15","author":"K Abe","year":"2014","unstructured":"Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7\u20138):610\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7","key":"901_CR86","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"G Writing","year":"2017","unstructured":"\u2022\u2022 Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505\u201312 This study led to the 2017 FDA approval of edaravone for use in ALS patients, the first FDA approved therapy for ALS in over 20 years. Despite the findings of this and prior studies suggesting that the benefits of this agent may be limited to a select subpopulation of ALS subjects with early disease, the drug was approved for use in all ALS paptients. This has generated a fair amount of controversy on many fronts. Practices vary across different providers and designated criteria to obtain coverage for the drug also varies between different payers.","journal-title":"Lancet Neurol"},{"issue":"sup1","key":"901_CR87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/21678421.2017.1364269","volume":"18","author":"Writing Group On Behalf Of The Edaravone Als 19 Study G","year":"2017","unstructured":"Writing Group On Behalf Of The Edaravone Als 19 Study G. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):55\u201363.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"901_CR88","unstructured":"Administration USFaD. Edaravone Prescribing Information. https:\/\/www.fda.gov\/default.htm2017 ."},{"issue":"sup1","key":"901_CR89","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/21678421.2017.1361446","volume":"18","author":"NJ Maragakis","year":"2017","unstructured":"Maragakis NJ. What can we learn from the edaravone development program for ALS? Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):98\u2013103.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"9 Suppl","key":"901_CR90","first-page":"S175","volume":"24","author":"BR Brooks","year":"2018","unstructured":"Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy\u2014a roundtable discussion. Am J Manag Care. 2018;24(9 Suppl):S175\u2013S86.","journal-title":"Am J Manag Care"},{"issue":"8","key":"901_CR91","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116(8):2290\u20136.","journal-title":"J Clin Invest"},{"issue":"5","key":"901_CR92","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435\u201342.","journal-title":"Lancet Neurol"},{"issue":"8","key":"901_CR93","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"\u2022\u2022 McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558\u201367 This study shows impressive preclinical data on the efficacy of a newer generation ASO, now in human trials, on multiple outcome measures in SOD1 animal models.","journal-title":"J Clin Invest"},{"issue":"2","key":"901_CR94","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","volume":"80","author":"CJ Donnelly","year":"2013","unstructured":"Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, et al. RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415\u201328.","journal-title":"Neuron"},{"issue":"47","key":"901_CR95","doi-asserted-by":"crossref","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","volume":"110","author":"C Lagier-Tourenne","year":"2013","unstructured":"Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110(47):E4530\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"901_CR96","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12035-014-8724-7","volume":"50","author":"G Riboldi","year":"2014","unstructured":"Riboldi G, Zanetta C, Ranieri M, Nizzardo M, Simone C, Magri F, et al. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS\/FTD diseases. Mol Neurobiol. 2014;50(3):721\u201332.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"901_CR97","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","volume":"90","author":"J Jiang","year":"2016","unstructured":"\u2022 Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90(3):535\u201350 This study demonstrated the efficacy of ASOs in correcting the pathogenic sequelae of C9 pathogenic expansions, an integral step in the pathway towards development of the C9 ASO now being tested in a Phase 1 clinical trial.","journal-title":"Neuron"},{"key":"901_CR98","unstructured":"Filing of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) to the European Medicines Agency (EMA) [press release]. http:\/\/www.ab-science.com\/file_bdd\/content\/1475163914_ABSCIENCESLAEMAFilingvEngVF.pdf . 2016."},{"key":"901_CR99","unstructured":"AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis [press release]. http:\/\/www.ab-science.com\/file_bdd\/content\/1527524735_CPALSUpdateVEngVF.pdf . 2018."},{"issue":"3","key":"901_CR100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaneurol.2015.4321","volume":"73","author":"P Petrou","year":"2016","unstructured":"Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1\/2 and 2a clinical trials. JAMA Neurol. 2016;73(3):337\u201344.","journal-title":"JAMA Neurol"},{"issue":"6","key":"901_CR101","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5966\/sctm.2014-0212","volume":"4","author":"KW Oh","year":"2015","unstructured":"Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015;4(6):590\u20137.","journal-title":"Stem Cells Transl Med"},{"key":"901_CR102","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Oh KW, Noh MY, Kwon MS, Kim HY, Oh SI, Park J, et al. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Ann Neurol. 2018; This is a successful phase 2 randomized controlled trial of repeated, intrathecally administered mesencyhmal stem cells in ALS subjects. The treatment group showed a statistically significant slower decline in the ALSFRS at 4 months and 6 months, relative to the control group. The findings of the trial justify a definitive phase 3 trial.","DOI":"10.1002\/ana.25302"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-018-0901-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-018-0901-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-018-0901-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T03:54:06Z","timestamp":1662263646000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-018-0901-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":102,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1007\/s11910-018-0901-z","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"17 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Robert C. Bucelli reports personal fees from MT Pharma, non-financial support from Biogen, outside the submitted work, and works closely with Tim Miller, MD, PhD at Wash U and cited a number of important ALS studies published by Dr. Miller\u2019s group in recent years. Matthew Burford reports non-financial support from Brainstorn-Cell Therapeutics, non-financial support from Biogen, non-financial support from Cedars-Sinai Medical Center, outside the submitted work, and has worked closely with Tim MIller, MD, PhD at Wash U as well as Robert Baloh, MD, PhD at Cedars-Sinai and cited several studies published by Dr. Miller\u2019s and Dr. Baloh\u2019s groups. Rocio Garcia-Santibanez declares no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"93"}}